Navigation Links
FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
Date:3/3/2008

ll University's Weill School of Medicine.

"The FluoroPharma team is pleased and encouraged by the Phase I results of the company's lead product," said Ljiljana Kundakovic, PhD, President of FluoroPharma. "We look forward to advancing two other cardiovascular PET molecular imaging agents -- BFPET for assessment of myocardial perfusion and VasoPET for assessment of atherosclerotic plaque formation."

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries. http://www.fluoropharma.com

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue relianc
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... IRVING, Texas , Sept. 17, 2014 /PRNewswire/ ... Physician Direct Accountable Care Organization (Physician Direct ACO) ... help their physicians in providing better care while ... Physician Direct Accountable Care ... Physician Network Services (OPNS). The OPNS mission is ...
(Date:9/17/2014)... , Sept. 17, 2014   MedeAnalytics ... solution that brings complete visibility to a provider,s ... an ever-evolving reimbursement landscape. Powered by the industry,s ... to the critical point between patient access and ... The solution will improve revenue capture, minimize audit ...
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2
(Date:9/17/2014)... September 17, 2014 Functional Fitness Solution ... and Dr. Cody Sipe that is helping middle-aged adults minimize ... longevity has caught the attention of Shane Michaels, prompting an ... their 50s, 60s, or even 70s what would be the ... a day-to-day basis, they would probably answer that the just ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In its latest ... programs and believes that having family close by during a ... or not the process is successful, is highlighting a member ... difference in the lives of addicts across the country and ... pet therapy can reduce the blood pressure, heart rate, and ...
(Date:9/17/2014)... that guard against damage to the ends of chromosomes could ... the deadliest form of skin cancer according to ... study has uncovered an important new genetic risk factor for ... count are the strongest indicators of those most at risk ... care in the sun, as they burn more easily. , ...
(Date:9/17/2014)... 2014 The Oliver Law Group P.C. ... caused by Non-Sterile Other-Sonic Ultrasound Transmission Gel to ... options for legal recourse. Other-Sonic ultrasound gel was recalled ... March 2012, after the product was linked to a ... Hospital in Royal Oak, Michigan . While victims of ...
(Date:9/17/2014)... Rockville Centre, NY (PRWEB) September 17, 2014 ... the court acknowledges that “bi-weekly telephonic discovery conferences would ... scheduled seven such conferences through mid-December. “At the end ... counsel will assess the need for additional conferences. ... the court recognizes that there is still much to ...
Breaking Medicine News(10 mins):Health News:Functional Fitness Solution: Review Exposes Dr. Dan Ritchie and Dr. Cody Sipe’s Guide to Everyday Fitness for Longevity 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2
... constipation are more likely to get diagnosed with the progressive ... have// some effect on the function of the gut long ... led the research, said: "It could help us more effectively ... high risk of developing the disease in the future." The ...
... type of childhood brain cancer has a unique molecule ... fight it.// Armed with targeted molecular treatments, doctors may ... side effects of prolonged and powerful radiation and chemotherapy ... a collaborative effort looking at a type of childhood ...
... A new invenvtion in the medical history. A team of ... a 68-year old woman using a remote controlled robot. This ... medical history. The operation took place at the European Institute ... it is a phenomenal step and we cannot even begin ...
... the Institute of Health Sciences in Oxford found that women ... to have a stillbirth, or to develop pre-eclampsia.// Taking low-dose ... researchers. ,The researchers reviewed more than 23 previous ... of anti-platelet drugs, of which low-dose aspirin is the most ...
... errors in the alpha gene are the cause of premature ... affects about 2% of the total population.// ,The University ... development of a genetic test, which would allow women with ... are at risk. They analysed DNA from women who had ...
... and marketing rights of the anti-anthrax vaccine developed by the ... is expected that the vaccine would be in the market ... to JNU for the exclusive rights. In addition, it will ... is yet to make any projections on the business the ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: